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Urinary bladder cancerAbstract Background: Exosomes are rich sources of biological material (proteins and nucleic
acids) secreted by both tumor and normal cells, and found in urine of urinary bladder cancer
patients.
Objective: The objective of the study was to identify interacting exosomal proteins in bladder can-
cer for future use in targeted therapy.
Methods: The Exocarta database (www.exocarta.org) was mined for urinary bladder cancer speci-
ﬁc exosomal proteins. The urinary bladder cancer speciﬁc exosomal proteins (n= 248) were ana-
lyzed to identify enriched pathways by Onto-tool Pathway Express (http://vortex.cs.wayne.edu/
ontoexpress).
Results: Enriched pathways included cellular architecture, motility, cell to cell adhesion, tumorige-
nesis and metastasis. Proteins in the 9 top-ranked pathways included CTNNA1 (alpha-catenin),
CTNNB1 (beta-catenin), VSAP, ITGA4, PAK1, DDR1, CDC42, RHOA, NRAS, RHO,
PIK3AR1, MLC1, MMRN1, and CTTNBP2 and network analysis revealed 10 important hub pro-
teins and identiﬁed inferred interactor NF2.
Conclusions: The importance of identifying interactors is that that they can be used as targets for
therapy, for example, using Bevacizumab (avastin – an angiogenesis inhibitor) against NF2 to inhi-
bit protein–protein interactions will inhibit tumor growth and progression by hindering the exo-
some biogenesis.
ª 2015 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Exosomes are microvesicles shed by vesiculation events from
various living cells secreted by most cell types, both cancerous
and normal and secreted in biological ﬂuids [1] and are
thought to play important roles in intercellular communica-
tions. They are generated via diverse biological mechanisms
triggered by pathways involved in oncogenic transformation,
microenvironmental stimulation, cellular activation, stress, or
Figure 1 Study design for identiﬁcation of exosomal proteins in
bladder cancer.
52 N. Kumari et al.death [2]. Biogenesis of the exosome begins with the secretion
of signal peptide proteins in the cytoplasm. Intraluminal vesi-
cles (ILVs) are formed through inward budding of endosomes
to form multivesicular bodies (MVBs) or multivesicular endo-
somes (MVE). The MVB fuses with the cellular membrane,
and the exosomes are released. MVBs can also be either
degraded (by fusion with lysosomes) or recycled [3].
Although exosomes were originally described in 1983, inter-
est in these vesicles has increased dramatically in the last few
years, after the ﬁnding that they contain RNA, protein, lipid
and other biomolecules [4]. It is clear that exosomes have spe-
cialized functions and play a key role in intercellular signaling
and waste management. It is also well accepted that urinary
exosomes (UEs) may be used as a novel biomarker source
for early disease detection, classiﬁcation, prediction severity,
outcome and response to treatment [5]. Consequently, there
is a growing interest in the clinical application of exosomes
as it can potentially be used for prognosis, therapy, and as
biomarkers for health and disease.
Cell-derived vesicles are released in many and perhaps all
biological ﬂuids, including blood [6], urine [1], breast milk
[7], malignant ascites [8,9], amniotic ﬂuid [10], bronchoalveolar
lavage ﬂuid [11] and culture medium supernatant in cell cul-
tures [12,13]. The content and secretion of these vesicles are
dependent on cellular origin. It may be hypothesized that exo-
somes present in the urine may be secreted from any of the
abdominal and pelvic organs such as the kidney, prostate,
ovary, and urinary bladder. Studies were done on identiﬁca-
tion of exosomal proteins, since the ﬁrst publication on pro-
teomic proﬁling of UEs by Pisitkun et al., [1] while
Mathivanan et al., [14] created a database, named ‘‘Exocarta’’
speciﬁcally for exosomes. Vesiclepedia database and urinary
exosome protein database also contain information about exo-
somes, but these databases include those proteins which are
also in the Exocarta database.
Urinary bladder cancer is the sixth most leading cancer in
India and the second most common malignancy of the
genitourinary tract [15] with a high recurrence rate. Urine cytol-
ogy and cystoscopy along with biopsy are commonly used diag-
nostic and monitoring tools, but cytology has a sensitivity of
only 29% [16] and cystoscopy is an invasive procedure. Hence,
there is a diagnostic need of early detection markers which
helps in surveillance of patients. Urinary exosomes may origi-
nate from the lining of the urinary tract, including glomerular
podocytes, renal tubule cells, and urinary bladder. The number
and content of UEs may change over time in association with
disorders that affect the urinary system. Most of the membrane
and cytoplasmic proteins of tumor cells will be excreted into
urine by the process of endo and exocytosis making the
microvesicles and exosomes a rich source of cancer-speciﬁc pro-
teins [1,2,5]. Exosomes speciﬁcally secreted by the bladder lin-
ing or urinary bladder cancer cells into the urine may be the
result of the interaction of some speciﬁc pathways. Identiﬁca-
tion of the interacting molecules of these pathways will identify
targets of therapeutic interest and prevent tumor progression.
Data available on Exocarta database was analyzed using
computational tools. Pathway based studies and system biol-
ogy approach were performed to identify exosomal proteins
speciﬁc to urinary bladder cancer. The present study identiﬁes
urinary bladder cancer-speciﬁc urinary exosomal proteins and
analysis of their interactions revealed proteins which can be
used as therapeutic targets.Methodology
Fig. 1 provides the study design employed for identifying
important proteins in urinary exosomes.
Exosomal proteins present in the urine were identiﬁed from
the Exocarta database (www.exocarta.org) [1]. A seed list was
prepared by selecting exosomal proteins speciﬁc only for blad-
der cancer. The ‘seed list’ was imported to the Pathway-Ex-
press module of Onto-tool (http://vortex.cs.wayne.edu/
projects.htm) and the pathways in which exosomal proteins
were involved were identiﬁed [17]. Impact factor was calculat-
ed by the web-based software (Pathway-Express module) using
both a statistically signiﬁcant number of differentially
expressed genes and biologically meaningful changes on a
given pathway. Pathway-Express provides two types of p-val-
ues for each pathway: (i) p-value obtained using the classical
statistics (referred to as classical p-value) and (ii) p-value
obtained using the impact analysis (referred to as gamma p-
value). The classical p-value is calculated as an over-represen-
tation analysis using hypergeometric test. The gamma p-value
is the p-value provided by the impact analysis [18].
Exosomal proteins involved in pathways with the high
impact factor (cutoff >10), were selected for studying pro-
tein–protein interactions (PPIs) network and hubs. Protein–
protein interactions (PPIs) were commonly understood as phy-
sical contacts with molecular docking between proteins that
occur in a cell or in a living organism in vivo [19]. Each of these
interactions is speciﬁcally adapted to carry out certain biologi-
cal functions. A PPI network is represented with proteins as
nodes and interactions between nodes as the edges. The com-
mon proteins among top 9 pathways were further studied by
a web-based software, POINeT (poinet.bioinformatics/tw).
The number of iterations used was one i.e., only ﬁrst degree
neighbors of queried nodes were searched. The protein–protein
interaction (PPI) information collected is integrated by various
protein databases to provide PPI ﬁltering and network
Exosomal proteins in bladder cancer therapy 53topology analysis capability [20]. PPI was ﬁltered for a number
of literatures (>1), shared GO (Gene Ontology) terms (>1)
and for interactors within the same species (Human). Graph
centrality values average distance, index of aggregation, con-
nectivity, cluster coefﬁcient and degree of each subnetwork
were computed.
The PPI network was visualized using the Cytoscape soft-
ware (2.8.2 version) as an undirected graph in a force-directed
layout [21]. It evaluated node essentiality by topological char-
acters. The degree of a node was the number of links incident
to this node in a network and identiﬁed hub nodes which are
highly connected nodes in a network and vital for the proper
function of a network [22]. Top 10 nodes ranked by degree
scores were identiﬁed as hubs. Node centrality values were cal-
culated in Cytoscape using the Network Analysis and
cytoHubba plugin [23]. In network analysis, node color was
based on Degree and intensity on Betweenness.
Results
A total of 4505 exosomal proteins are reported in the Exocarta
database, of which 1152 were reported in the urine and 248
were reported speciﬁc to bladder cancer. The urinary bladder
cancer speciﬁc exosomal proteins were taken as the seed pro-
tein list for identiﬁcation of signaling pathways involved in
exosome formation and secretion. Pathway-Express moduleFigure 2 Pathway analysis by using the web tool Pathway Express
involved in each pathway.from Onto-tools (http://vortex.cs.wayne.edu/ontoexpress)
was used to identify the pathways which were most signiﬁcant-
ly involved. Impact factor was calculated by the Pathway-Ex-
press module and 9 Pathways having impact factor >10 were
found to be signiﬁcantly involved (Fig. 2 and Table 1). Out of
248 bladder cancer speciﬁc exosomal proteins, 16 are involved
in regulation of the actin cytoskeleton, 13 in tight junction, 14
in focal adhesion, 11 in leukocytes transendothelial migration,
8 in adherens junction, 8 in ECM receptor interaction, 13 in
pathways in cancer, 6 in Shigellosis and 6 in Pathogenic
Escherichia coli interaction pathways (Fig. 3). These 9 path-
ways had a total number of 88 proteins, of which 14 were pro-
teins interacting in more than one of the pathways and
included A-catenin/CTNNA1, B-catenin/CTNNB1, Rho,
RhoA, cdc42, ECM/MMRN1, Ras/N-Ras, Rac/ P21/PAK1,
RTK/DDR1, VASP MLC/MLC1, ITGA4, PIK3C2A/MLCP
and CTTNBP2/Cortactin (Table 2).
Protein–protein interaction network analysis and visualization in
cytoscape
The 14 common proteins were used for graphic visualization of
the network in Cytoscape. All protein–protein interactions
showed one large network by CTNNA1, CTNNB1, VSAP,
ITGA4, PAK1, DDR1, CDC42, RHOA, NRAS, RHO and
PIK3AR1 and 3 small networks by MLC1, MMRN1, andshows the impact factor of involved pathways and the proteins
Table 1 Pathway enriched by urinary bladder cancer speciﬁc
exosomal proteins (n= 248).
S.No. Pathways Input genes/
pathway genes
Impact
factor
P-value
1 Regulation of actin
cytoskeleton
16/217 20.75 2.11E8
2 Tight junction 13/135 20.34 3.11E8
3 Focal adhesion 14/203 17.47 4.77E7
4 Leukocytes endothelial
migration
11/119 16.98 7.55E7
5 Adherens junction 8/78 13.49 2.01E7
6 ECM receptor 8/84 12.92 3.39E5
7 Pathway in cancer 14/330 11.63 1.11E4
8 Shigellosis 6/54 10.88 2.22E4
9 Pathogenic E. coli
interaction
6/54 10.88 2.22E4
Figure 3 Pie diagram showing the percentage of proteins in each
pathway involved in bladder cancer.
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54 N. Kumari et al.CTTNBP2. In the large network, CDC42, CTNNB1, RHOA
and PAK1 were hub proteins, showed maximum interaction
with other proteins (Fig. 4). Small hubs were formed by pro-
teins VASP, KRAS, ITGA4, DDR1 and RHO, whereas
PIK3C2A interacted only with PAK1 and CTNNB1 in a large
network through EGFR. Hub proteins of the large network
were connected by a number of inferred proteins. Feedback
loops were formed by CTNNA1, DDR1, ITGA4, VASP,
PAK1, RHOA and CDC42. All protein–protein interactions
were complex due to a large number of interactions; hence
the network was revisualized as ﬁltered protein–protein inter-
actions (ﬁltered-PPI) (Fig. 5). It showed 8 proteins in the net-
work among 14 proteins. Among these MLC1, CTTNBP2 and
MMRN1 were found to form small individual networks. In ﬁl-
tered-PPI, only 4 hub proteins were present (CTNNA1,
CTNNB1, CDC42 and PAK1), in which direct interactions
were found between CTNNB1 and CTNNA1; CDC42 and
PAK1 whereas PAK1 and B-catenin interacted through
inferred protein NF2. A-catenin and PAK1 formed a self loop
in the large network. KRAS, RHOA, RHO and VASP formed
smaller networks individually.
CytoHubba plugin was used to rank the proteins on the
basis of four different centrality values – Degree, Betweenness,
Closeness and Bottleneck (Table 3). B-catenin, CDC42 and
Figure 4 Network diagram showing all the interactions of the common exosomal proteins in the involved pathways and their
interaction.
Exosomal proteins in bladder cancer therapy 55PAK1 were ranked as the important proteins on the basis of
Degree, Betweenness, Closeness, Bottleneck and Sum rank.
Filtered-PPI and centrality value showed B-catenin-PAK1-
CDC42 had the highest sum of Degree, Betweenness, Close-
ness and Bottleneck. All three also interacted both with
inferred protein NF2 and A-catenin. Hence, it was found that
A-catenin, B-catenin, NF2, Pak1 and CDC42 are the most
important proteins.
Discussion
Exosomes are highly complex nanometer-sized vesicles that are
ubiquitous in biological systems. There is considerable interest
to understand the physiological functions of exosomes in var-
ious cancers. Few studies of exosomes in various malignancies
like prostate, breast, and colorectal cancers, melanoma, pleural
mesothelioma, malignancies of the central nervous system, and
others have been reported. The proteins associated with blad-
der cancer diseases could be detected on exosomes isolated
from urine, indicating a possible use for urine exosomes as
biomarkers [6,13,14]. For instance, Pisitkun et al. demonstrat-
ed the excretion of exosomes containing aquaporin-2 proteinin autosomal dominant and autosomal recessive nephrogenic
diabetes insipidus patients [1]. Similar proteomic studies per-
formed on urinary exosomes generated molecular signatures,
illustrating valuable potential for diagnostic, prognostic and
pathophysiological discovery.
Exosomes secreted by tumor cells are present in the urine
and make a microenvironment in the bladder and may come
in contact with the normal epithelial lining. While the mechan-
ism of interaction of tumor and normal cells with exosomes is
still not clear, it is possible that exosomes bind with speciﬁc
ligands to cell surfaces. Upon binding, exosomes can enter tar-
get cells in one of two ways: by being taken up by the target
cell’s endocytic pathway or by fusing to the target cell’s mem-
brane and releasing its contents directly into the cytoplasm.
Exosomes are increasingly recognized as mediators of intercel-
lular communication due to their capacity to merge with and
transfer a repertoire of bioactive molecular content (cargo)
to recipient cells [24,25].
Exosomal proteins and gene expression have been reported
to be increased in cancers and may be due to the secretion of
exosomes at an increased rate by tumor cells undergoing active
proliferation and invasion. The acquisition of a motile and
Figure 5 Network diagram of the ﬁltered PPI showing hub proteins CTNNB1, PAK1 and CDC42. Inferred protein NF2 is seen between
CTNNB1 and PAK1.
56 N. Kumari et al.invasive phenotype is an important step in the development of
tumors and ultimately metastasis. This step requires the abro-
gation of cell–cell contacts, the remodeling of the extracellular
matrix and of cell-matrix interactions, and ﬁnally the move-
ment of the cell mediated by the regulation of actin cytoskele-
ton. The 9 pathways enriched included motility, cell to cell
contact, metastasis receptor interaction and tumorigenesis.
A-catenin and B-catenin are described to be associated with
enhanced cell motility and cancer invasion, especially inpatients with a cytoplasmic localization of this protein [26].
These cytoskeleton proteins may provide infrastructure for
exosome formation and their cell to cell movement.
The tight junction is an intracellular junctional structure
that mediates adhesion between epithelial cells and perme-
ability across epithelial cell sheets. Microparticles or exosomes
originated from leukocytes can induce differential effects on
endothelial function and promote angiogenesis. The adherens
junction is an element of the cell–cell junction in which
Table 3 Centrality values of top 10 proteins ranked by
Degree, Closeness, Betweenness, Bottle neck and Sum of
centrality score.
Degree Betweenness Closeness Bottle neck Sum
CTNNB1 CTNNB1 CTNNB1 CTNNB1 CTNNB1
CDC42 CDC42 CDC42 CDC42 CDC42
RHOA PAK1 PAK1 PAK1 PAK1
PAK1 RHOA RHOA RICS RHOA
VASP VASP RICS ERBB2 VASP
CTNNA1 KRAS TGFBR1 FAS CTNNA1
DDR1 ITGA4 PARD3 RHOA DDR1
ITGA4 DDR1 IQGAP1 FLNA ITGA4
KRAS RHO TRIP10 VCL KRAS
RHO RICS PIK3R1 VASP RHO
Exosomal proteins in bladder cancer therapy 57cadherin receptors bridge the neighboring plasma membranes
via their homophilic interactions. Cadherins associate with
cytoplasmic proteins, called catenins, which in turn bind to
cytoskeletal components, such as actin ﬁlaments and micro-
tubules [27]. These molecular complexes further interact with
other proteins, including signaling molecules. The regulatory
mechanism of adherens junction may contribute to normal
morphogenetic cell behavior as well as to the pathogenic
one, such as cancer invasion and metastasis [28]. The extracel-
lular matrix (ECM) consists of a complex mixture of structural
and functional macromolecules and serves an important role in
adhesion, migration, differentiation, proliferation, and apop-
tosis. ‘Pathway in cancer’ explains that cell growth and sur-
vival are regulated by complex signaling pathways that can
be disrupted to cause cancer [29]. The pathway in cancer reg-
ulates cell proliferation, migration, apoptosis, and differen-
tiation and any aberration in the pathway may cause
uncontrolled cell growth. Almost 7 pathways explain the
exosomal biogenesis, their speciﬁc secretion from tumorigenic
environment. Proteins involved in Shigellosis and Pathogenic
E. coli interaction pathways may explain their presence in uri-
nary exosomes caused by bacterial infection found to occur
frequently in these patients [30].
Network analysis identiﬁed interacting proteins and subnet-
works. The four proteins involved in the large network includ-
ed B-catenin which is a component of the cadherin-based
adherens junction complexes that form at cell–cell adhesion
sites. Intracellular proteins like CD8 and CD9 (a protein
present in exosome in almost all lower abdominal cancers),
inhibit Wnt signaling and its inhibition reduces the cellular
pool of B-catenin by enhancing the exosome-associated export
of B-catenin from the cell [31]. A-catenin is a linking protein
between cadherins and actin-containing ﬁlaments of the
cytoskeleton are involved in the formation of exosomes. These
proteins play a major role in the actin cytoskeleton, cell–cell
adhesion and pathways in cancer. A-catenin and B-catenin
interact with each other and form a cadherin–catenin complex
which further activates and interacts with the known oncopro-
teins cdc42-rac1-pak1. cdc42 (a Cell division control protein 42
homolog) has a role in cell division in normal conditions, but
in adverse conditions it is involved in exosomal complex for-
mation by various pathways. Target molecules for Cdc42 have
been identiﬁed to be p21-activated kinase. This gene encodes a
family member of serine/threonine p21-activating kinases,
known as PAK proteins. These proteins are critical effectorsthat link RhoGTPases to cytoskeleton reorganization and
nuclear signaling, and they serve as targets for the small
GTP binding proteins Cdc42 [32,33]. A-catenin regulates cell
proliferation by reducing B-catenin transcriptional activity,
cdc42 and other oncogenes. It is also reported that loss of B-
catenin may cause prostate cancer [33] and bladder cancer.
NF2, interacting between B-catenin and PAK1, has been
shown to act as a tumor suppressor primarily through its func-
tions as a cytoskeletal scaffold. It also associates with a down-
stream effector of Rho small G proteins, which is associated
with the formation of stress ﬁbers and cytokinesis [34].
The inferred protein NF2 was not reported in urine and
may not be present in exosomes but their presence in cells
may be necessary for the formation of exosomes or for cellular
proliferation. NF2 causes a genetic disorder called neuroﬁbro-
matoses that cause tumors to grow along nerves and produce
other abnormalities such as skin changes and bone deformities
[34]. Exact role of NF2 in bladder cancer patients is still not
known but network analysis suggests a crucial role for this
protein in the uncontrolled function of oncogene and cell cycle
regulators. Targeted therapy at the check points by using drugs
or monoclonal antibodies may block the growth and spread of
cancer by interfering with speciﬁc molecules involved in tumor
growth and progression. Bevacizumab (avastin) is an angio-
genesis inhibitor used as a tumor growth inhibitor in colorectal
cancer, rectal cancer, metastatic breast and lung cancer in com-
bination with Capecitabine [35,36,37]. The presence of proteins
in urinary exosomes likely to act with NF2 may suggest a role
for Bevacizumab therapy in bladder cancer. Hence, we can use
Bevacizumab therapy that might be useful as a targeted ther-
apy against NF2 in urothelial cancer. However, further func-
tional study to establish the role of this protein in bladder
cancer should be accompanied by the role of Bevacizumab in
suppressing tumor growth.Conclusion
This preliminary analysis showed the presence of exosomal
proteins alpha-catenin, beta-catenin, PAK1, CDC42 and
inferred protein NF2 in the urine to be of importance in the
biology of the tumor. However, the importance of these pro-
teins in monitoring and therapy has to be elucidated on a large
cohort of clinical samples. Targeted therapy of NF2 with
monoclonal antibodies should also be explored for clinical
application.Conﬂict of interest
None.
References
[1] Pisitkun T, Shen RF, Knepper MA. Identiﬁcation and
proteomic proﬁling of exosomes in human urine. Proc. Natl.
Acad. Sci 2004;101:13368–73.
[2] Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth
J, et al. Proteomics analysis of bladder cancer exosomes. Mol
Cell Proteomics 2010;9:1324–38.
[3] Kellera Sascha, Sandersona Michael P, Stoecka Alexander,
Altevogta Peter. Exosomes: from biogenesis and secretion to
biological function. Immunol Lett 2006;107:102–8.
58 N. Kumari et al.[4] Thery Clotilde. Exosomes: secreted vesicles and intercellular
communications. F1000 Biol Rep 2011;3:3–15.
[5] Dimov Irena, Jankovic Velickovic Ljubinka, Stefanovic
Vladisav. Urinary exosomes. Sci World J 2009;9:1107–18.
[6] Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G,
Bonnerot C. Exosomal-like vesicles are present in human
blood plasma. Int Immunol 2005;17:879–87.
[7] Admyre C, Johansson SM, Qazi KR, File´n JJ, Lahesmaa R,
Norman M, et al. Exosomes with immune modulatory features
are present in human breast milk. J Immunol 2007;179:1969–78.
[8] Andre F, Schartz NE, Movassagh M, Flament C, Pautier P,
Morice P, et al. Malignant effusions and immunogenic tumour-
derived exosomes. Lancet 2002;360:295–305.
[9] Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R,
Severijnen LA, et al. Proteomic analysis of exosomes isolated
from human malignant pleural effusions. Am J Respir Cell Mol
Biol 2004;31:114–21.
[10] Asea A, Jean-Pierre C, Kaur P, Rao P, Linhares IM, Skupski D,
et al. Heat shock protein-containing exosomes in midtrimester
amniotic ﬂuids. J Reprod Immunol 2008;79:12–7.
[11] Admyre C, Grunewald J, Thyberg J, Gripenba¨ck S, Tornling G,
Eklund A, et al. Exosomes with major histocompatibility
complex class II and co-stimulatory molecules are present in
human BAL ﬂuid. Eur Respir J 2003;22:578–83.
[12] Hosseini-Beheshti Elham, Pham Steven, Adomat Hans, Li Na,
Emma S, Tomlinson Guns. Exosomes as biomarker enriched
microvesicles: characterization of exosomal proteins derived
from a panel of prostate cell lines with distinct AR phenotypes.
Mol Cell Proteomics 2012;10:863–85.
[13] Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL,
Rameshwar P. Delivery of functional Anti-miR-9 by
mesenchymal stem cell-derived exosomes to glioblastoma
multiforme cells conferred chemosensitivity. Mol Ther Nucleic
Acids 2013;2:e126.
[14] Mathivanan S, Simpson RJ. ExoCarta: a compendium of
exosomal proteins and RNA. Proteomics 2009;9:4997–5000.
[15] Anastasiadis A, de Reijke TM. Best practice in the treatment of
nonmuscle invasive bladder cancer. Ther Adv Urol
2012;4:13–32.
[16] Mataka I, Bani-Hani K, Shotar A, Bani Hani O, Bani-Hani I.
Transitional cell carcinoma of the urinary bladder: a
clinicopathological study. Singapore Med J 2008;49:790–4.
[17] Khatri P, Sellamuthu S, Malhotra P, Amin K, Done A, Draghici
S. Recent additions and improvements to the Onto-Tools.
Nucleic Acids Res. 2005;33:762–5.
[18] Tarca AL, Draghici S, Khatri P, et al. A novel signaling
pathway impact analysis. Bioinformatics 2009;25(1):75–82.
[19] Lee SA, Chan CH, Chen TC, Yang CY, Huang KC, Tsai CH,
et al. POINeT: protein interactome with sub–network analysis
and hub prioritization. BMC Bioinformatics
2009;15:1471–2105.
[20] De Las Rivas J, Fontanillo C. Protein–protein interaction
networks: unraveling the wiring of molecular machines within
the cell. Brief Funct Genomics 2012;11:489–96.
[21] Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker TME.
Cytoscape 2.8: new features for data integration and network
visualization. Bioinformatics 2011;27:431–2.[22] Baraba´si AL, Oltvai ZN. Network biology: understanding the
cell’s functional organization. Nat Rev Genet 2004;5:101–13.
[23] Lin CY, Chin CH, Wu HH, Chen SH, Ho CW, KoMT. Hubba:
hub objects analyzer a framework of interactome hubs
identiﬁcation for network biology. Nucleic Acids Res
2008;36:438–43.
[24] Henderson MC, Azorsa DO. The genomic and proteomic
content of cancer cell-derived exosomes. Front Oncol 2012;2:38.
[25] Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: from
biogenesis and secretion to biological function. Immunol Lett
2006;107:102–8.
[26] Inge LJ, Rajasekaran SA, Wolle D, Barwe SP, Ryazantsev S,
Ewing CM, et al. Alpha-Catenin overrides Src-dependent
activation of beta-catenin oncogenic signaling. Mol Cancer
Ther 2008;7:1386–97.
[27] Meng W, Takeichi M. Adherens junction: molecular
architecture and regulation. Cold Spring Harb Perspect Biol
2009;1:a002899.
[28] Yonemura S, Itoh M, Nagafuchi A. Cell-to-cell adherens
junction formation and actin ﬁlament organization: similarities
and differences between non-polarized ﬁbroblasts and polarized
epithelial cells. J Cell Sci 1995;108:127–42.
[29] Bosman FT, Stamenkovic I. Functional structure and
composition of the extracellular matrix. J Pathol
2003;200:423–8.
[30] LExosomes: secreted vesicles and intercellular
communicationsiotta L A, Tumor invasion and metastases––
role of the extracellular matrix: Rhoads Memorial Award
lecture. Cancer Res 1986;46:1–7.
[31] Chairoungdua A, Smith DL, Pochard P, Hull M, Caplan MJ.
Exosome release of b-catenin: a novel mechanism that
antagonizes Wnt signaling. JCB 2010;190:1079–91.
[32] Benninger Y, Thurnherr T, Pereira JA, Krause S, Wu X,
Chrostek-Grashoff A, et al. Essential and distinct roles for
cdc42 and rac1 in the regulation of Schwann cell biology during
peripheral nervous system development. JBC 2007;177:1051–61.
[33] Francis JC, Thomsen MK, Taketo MM, Swain A. b-Catenin is
required for prostate development and cooperates with Pten loss
to drive invasive carcinoma. PLoS Genet 2013;9:e1003180.
[34] Klose A, Ahmadian MR, Schuelke M, Scheffzek K, Hoffmeyer
S, Gewies A, et al. Selective disactivation of neuroﬁbromin
GAP activity in neuroﬁbromatosis type 1 (NF1). Hum Mol
Genet 2010;7:1261–8.
[35] Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK,
Fehrenbacher L, et al. Randomized phase III trial of
capecitabine compared with bevacizumab plus capecitabine in
patients with previously treated metastatic breast cancer. J Clin
Oncol 2005;23:792–9.
[36] Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug
approval summary: bevacizumab (Avastin) plus carboplatin and
paclitaxel as ﬁrst-line treatment of advanced/metastatic
recurrent nonsquamous non-small cell lung cancer. Oncologist
2007;12:713–8.
[37] Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a
humanized anti-VEGFmonoclonal antibody for cancer therapy.
Biochem Biophys Res Commun 2005;333:328–35.
